Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution

Seminars in Liver Disease

Volumn 35, Issue 4, 2015, Pages 402-420

  Eslam, Mohammed ^a   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

genome wide association studies; hepatitis C virus

Indexed keywords

ANTIVIRUS AGENT; INTERFERON LAMBDA 4; PEGINTERFERON LAMBDA; UNCLASSIFIED DRUG; IFNL4 PROTEIN, HUMAN; IL28A PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERFERON; INTERLEUKIN DERIVATIVE;

ARTICLE; CHRONIC HEPATITIS C; CYTOPENIA; DISEASE COURSE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST PARASITE INTERACTION; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; COMPLICATION; CRYOGLOBULINEMIA; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LIVER CIRRHOSIS; VASCULITIS;

CRYOGLOBULINEMIA; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; VASCULITIS;

EID: 84949952642     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1567830     Document Type: Article

References (183)

1. Hajarizadeh B., Grebely J., Dore G. J. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol: 2013; 10 9 553 562
2. Cowie B. C., Allard N., MacLachlan J. H. European responses in focus: comparing viral hepatitis and HIV related deaths in Europe 1990-2010 in the Global Burden of Disease Study 2010. In: Proceedings of the 49th annual meeting of the European Association for the Study of the Liver; April 8-13, 2014; London, England
3. The Gastroenterological Society of Australia/Australian Liver Association (GESA/ALA) The economic cost and health burden of liver diseases in Australia. Kingston, Canberra, Australia Deloitte Access Economics: 2013
4. Ly K. N., Xing J., Klevens R. M., Jiles R. B., Ward J. W., Holmberg S. D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med: 2012; 156 4 271 278
5. Razavi H., Waked I., Sarrazin C., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat: 2014; 21 01 34 59
6. Waked I., Doss W., El-Sayed M. H., et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol: 2014; 15 2 45 52
7. Morin T., Pariente A., Lahmek P., Rabaud C., Silvain C., Cadranel J. F.; Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) Société de Pathologie Infectieuse de Langue Française (SPILF) Fédération des Pôles de Référence et Réseaux Hépatites (FPRRH). Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol: 2010; 22 2 157 166
8. Seeff L. B. The history of the natural history of hepatitis C (1968-2009). Liver Int: 2009; 29 01 89 99
9. Khattab M. A., Eslam M., Alavian S. M. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon: 2010; 10 4 258 269
10. Eslam M., Khattab M. A., Harrison S. A. Insulin resistance and hepatitis C: an evolving story. Gut: 2011; 60 8 1139 1151
11. Yoshida H., Tateishi R., Arakawa Y., et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut: 2004; 53 3 425 430
12. George S. L., Bacon B. R., Brunt E. M., Mihindukulasuriya K. L., Hoffmann J., Di Bisceglie A. M. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology: 2009; 49 3 729 738
13. Romero-Gómez M., Fernández-Rodríguez C. M., Andrade R. J., et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol: 2008; 48 5 721 727
14. Gragnani L., Fognani E., Piluso A., et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. Hepatology: 2015; 61 4 1145 1153
15. Armstrong G. L., Alter M. J., McQuillan G. M., Margolis H. S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology: 2000; 31 3 777 782
16. Liu C. H., Liu C. J., Lin C. L., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis: 2008; 47 10 1260 1269
17. Romero-Gomez M., Eslam M., Ruiz A., Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int: 2011; 31 4 443 460
18. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science: 1996; 273 5281 1516 1517
19. Haines J. L., Hauser M. A., Schmidt S., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science: 2005; 308 5720 419 421
20. Hindorff L. A., MacArthur J., Morales J., et al. A catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies. Accessed December 8, 2014
21. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet: 2008; 40 12 1461 1465
22. Ge D., Fellay J., Thompson A. J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature: 2009; 461 7262 399 401
23. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet: 2009; 41 10 1100 1104
24. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet: 2009; 41 10 1105 1109
25. Rauch A., Kutalik Z., Descombes P., et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology: 2010; 138 4 1338 1345, 1345.e1-1345.e7
26. Moghaddam A., Melum E., Reinton N., et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology: 2011; 53 3 746 754
27. Yu M. L., Huang C. F., Huang J. F., et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology: 2011; 53 1 7 13
28. Mangia A., Thompson A. J., Santoro R., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology: 2010; 139 3 821 827, 827.e1
29. Eslam M., Leung R., Romero-Gomez M., et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol: 2014; 61 2 235 241
30. Asselah T., De Muynck S., Broët P., et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol: 2012; 56 3 527 532
31. Seto W. K., Tsang O. T., Liu K., et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat: 2013; 20 7 470 477
32. Akkarathamrongsin S., Payungporn S., Thong V. D., et al. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms. World J Gastroenterol: 2014; 20 30 10599 10605
33. Antaki N., Bibert S., Kebbewar K., et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut: 2012; 61 11 1640 1641
34. Thompson A. J., Muir A. J., Sulkowski M. S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology: 2010; 139 1 120 129.e18
35. Duggal P., Thio C. L., Wojcik G. L., et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med: 2013; 158 4 235 245
36. Thomas D. L., Thio C. L., Martin M. P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature: 2009; 461 7265 798 801
37. Tillmann H. L., Thompson A. J., Patel K., et al. German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology: 2010; 139 5 1586 1592, 1592.e1
38. Grebely J., Page K., Sacks-Davis R., et al. InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology: 2014; 59 1 109 120
39. Rallón N. I., Naggie S., Benito J. M., et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS: 2010; 24 8 F23 F29
40. Guo X., Yang G., Yuan J., et al. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. PLoS ONE: 2013; 8 10 e77911
41. Poordad F., McCone J. Jr, Bacon B. R., et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1195 1206
42. Jacobson I. M., McHutchison J. G., Dusheiko G., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 25 2405 2416
43. Bacon B. R., Gordon S. C., Lawitz E., et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med: 2011; 364 13 1207 1217
44. Zeuzem S., Andreone P., Pol S., et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med: 2011; 364 25 2417 2428
45. Bota S., Sporea I., Şirli R., Neghinə A. M., Popescu A., Strəin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig: 2013; 33 5 325 331
46. Fried M. W., Buti M., Dore G. J., et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology: 2013; 58 6 1918 1929
47. Jacobson I. M., Gordon S. C., Kowdley K. V., et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med: 2013; 368 20 1867 1877
48. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med: 2013; 368 20 1878 1887
49. Zeuzem S., Soriano V., Asselah T., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med: 2013; 369 7 630 639
50. Sulkowski M. S., Asselah T., Lalezari J., et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology: 2013; 57 6 2143 2154
51. Meissner E. G., Bon D., Prokunina-Olsson L., et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis: 2014; 209 11 1700 1704
52. Chu T. W., Kulkarni R., Gane E. J., et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology: 2012; 142 4 790 795
53. 12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol: 2012; 56 (S2): 549 550
54. Chan K., Lai M. N., Groessl E. J., et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol: 2013; 11 11 1503 1510
55. Sroczynski G., Siebert U. Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nat Rev Gastroenterol Hepatol: 2013; 10 10 572 574
56. Petta S., Cabibbo G., Enea M., et al. WEF Study Group. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology: 2014; 59 5 1692 1705
57. Sonneveld M. J., Wong V. W., Woltman A. M., et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology: 2012; 142 3 513 520.e1
58. Lampertico P., Viganò M., Cheroni C., et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology: 2013; 57 3 890 896
59. Hwa Park N., Jae Kim C. IL28B polymorphisms are not associated with outcomes of hepatitis B virus infection. Hepatology: 2011; 54 1094A
60. Yapali S., Cetintas A., Salman E., et al. IL28B genotype has no impact on spontaneous hepatitis B surface antigen (HBSAG) clearance in inactive carriers: a long term, case matched retrospective cohort study. J Hepatol: 2012; 56 S193
61. Bochud P. Y., Bibert S., Kutalik Z., et al. Swiss Hepatitis C Cohort Study Group; ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology: 2012; 55 2 384 394
62. Noureddin M., Wright E. C., Alter H. J., et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology: 2013; 58 5 1548 1557
63. Thompson A. J., Clark P. J., Zhu M., et al. Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study. Hepatology: 2010; 52 4 1220A 1221A
64. Marabita F., Aghemo A., De Nicola S., et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology: 2011; 54 4 1127 1134
65. Di Marco V., Bronte F., Calvaruso V., et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica: 2012; 97 5 679 686
66. Fabris C., Falleti E., Cussigh A., et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol: 2011; 54 4 716 722
67. Falleti E., Bitetto D., Fabris C., et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol: 2011; 31 5 891 899
68. Abe H., Ochi H., Maekawa T., et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol: 2010; 53 3 439 443
69. Garrett M. E., Abdelmalek M. F., Ashley-Koch A., et al. IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. J Hepatol: 2013; 58 2 402 403
70. Petta S., Grimaudo S., Cammà C., et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol: 2012; 56 6 1356 1362
71. Eslam M., Hashem A. M., Leung R., et al. International Hepatitis C Genetics Consortium (IHCGC). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun: 2015; 6 6422
72. Guzmán-Fulgencio M., Berenguer J., García-Álvarez M., et al. IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. J Infect: 2013; 66 2 170 178
73. Bruno S., Thompson A. J., Critelli R., et al. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study. Antiviral Res: 2015; 113 27 32
74. Clausen L. N., Astvad K., Ladelund S., Larsen M. V., Schonning K., Benfield T. Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. AIDS: 2012; 26 12 1509 1516
75. Parczewski M., Bander D., Leszczyszyn-Pynka M., Urbańska A., Socha Ł, Boroń-Kaczmarska A. IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS Res Hum Retroviruses: 2012; 28 12 1640 1646
76. van der Meer A. J., Veldt B. J., Feld J. J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA: 2012; 308 24 2584 2593
77. Probst A., Dang T., Bochud M., Egger M., Negro F., Bochud P. Y. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat: 2011; 18 11 745 759
78. Lagging M., Askarieh G., Negro F., et al. DITTO-HCV Study Group. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE: 2011; 6 2 e17232
79. Hodo Y., Honda M., Tanaka A., et al. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res: 2013; 19 7 1827 1837
80. Chang K. C., Tseng P. L., Wu Y. Y., et al. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol: 2015; 13 5 1017 1024
81. Sato M., Kato N., Tateishi R., et al. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol: 2014; 49 4 748 754
82. Eurich D., Boas-Knoop S., Bahra M., et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation: 2012; 93 6 644 649
83. Ren S., Lu J., Du X., et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother: 2012; 61 9 1433 1439
84. Fukuhara T., Taketomi A., Motomura T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology: 2010; 139 5 1577 1585, 1585.e1-1585.e3
85. Eurich D., Boas-Knoop S., Ruehl M., et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl: 2011; 17 3 289 298
86. Charlton M. R., Thompson A., Veldt B. J., et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology: 2011; 53 1 317 324
87. Duarte-Rojo A., Veldt B. J., Goldstein D. D., et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation: 2012; 94 2 197 203
88. Lange C. M., Moradpour D., Doehring A., et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol: 2011; 55 2 322 327
89. Layden J. E., Tayo B. O., Cotler S. J., et al. Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation: 2014; 97 10 1072 1078
90. Veldt B. J., Duarte-Rojo A., Thompson A. J., et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant: 2012; 12 3 737 744
91. Duca A. M., de la Fuente S., Citores M. J., et al. CC genotype at rs12979860 of IL28B is associated with lower risk of new-onset diabetes after transplantation in adult patients with liver transplantation for hepatitis C cirrhosis. Transplant Proc: 2014; 46 9 3114 3116
92. Watt K. D., Dierkhising R., Fan C., et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant: 2013; 13 9 2450 2457
93. Piluso A., Giannini C., Fognani E., et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat: 2013; 20 4 e107 e114
94. Sansonno D., Russi S., Serviddio G., et al. Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis. J Rheumatol: 2014; 41 1 91 98
95. Li J. H., Lao X. Q., Tillmann H. L., et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology: 2010; 51 6 1904 1911
96. Saito H., Ito K., Aoki Y., et al. IL28B polymorphism is associated with the level of LDL cholesterol and the important predictor for the PEG-IFN/RBV treatment with chronic hepatitis. Hepatology: 2010; 52 4 732A
97. Sheridan D. A., Bridge S. H., Felmlee D. J., et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol: 2012; 57 1 32 38
98. Chiba-Falek O., Linnertz C., Guyton J., et al. Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet: 2012; 131 12 1911 1920
99. Tillmann H. L., Patel K., Muir A. J., et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol: 2011; 55 6 1195 1200
100. Petta S., Rosso C., Leung R., et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol: 2013; 11 3 311 317.e1
101. Stättermayer A. F., Rutter K., Beinhardt S., et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol: 2012; 57 3 492 498
102. Toyoda H., Kumada T. Favorable association between genetic polymorphisms near the IL28B gene and hepatic steatosis: direct or indirect? J Hepatol: 2012; 56 3 738 739, author reply 739
103. Ampuero J., Rojas L., Calle R., et al. 439 I148M PNPLA3 variant promotes steatosis according to viral and IL28B genotype but does not affect sustained viral response in patients with hepatitis C. J Hepatol: 2013; 58 01 S180
104. Veldt B. J., Duarte-Rojo A., Thompson A. J., et al. Donor IL28B TT-polymorphism is associated with increased incidence of hepatic steatosis in liver transplant patients with chronic hepatitis C. J Hepatol: 2013; 58 01 S207 S208
105. Valenti L., Aghemo A., Stättermayer A. F. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol: 2012; 56 5 1209 1210, author reply 1210-1212
106. Ampuero J., Del Campo J. A., Rojas L., et al. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Ann Hepatol: 2014; 13 4 356 363
107. Ogawa E., Furusyo N., Murata M., et al. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol: 2012; 57 3 534 540
108. Huang J. F., Yu M. L., Huang C. F., et al. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int: 2012; 32 6 962 969
109. Honda M., Sakai A., Yamashita T., et al. Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology: 2010; 139 2 499 509
110. Urban T. J., Thompson A. J., Bradrick S. S., et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology: 2010; 52 6 1888 1896
111. Honda M., Shirasaki T., Shimakami T., et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology: 2014; 59 3 828 838
112. McGilvray I., Feld J. J., Chen L., et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology: 2012; 142 5 1122 1131.e1
113. Raglow Z., Thoma-Perry C., Gilroy R., Wan Y. J. IL28B genotype and the expression of ISGs in normal liver. Liver Int: 2013; 33 7 991 998
114. Zhang S., Kodys K., Li K., Szabo G. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology: 2013; 144 2 414 425.e7
115. Yoshio S., Kanto T., Kuroda S., et al. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology: 2013; 57 5 1705 1715
116. Murata K., Sugiyama M., Kimura T., et al. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. J Gastroenterol: 2014; 49 1 126 137
117. Watanabe T., Sugauchi F., Tanaka Y., et al. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut: 2013; 62 9 1340 1346
118. Prokunina-Olsson L., Muchmore B., Tang W., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet: 2013; 45 2 164 171
119. Bibert S., Roger T., Calandra T., et al. Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med: 2013; 210 6 1109 1116
120. McFarland A. P., Horner S. M., Jarret A., et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol: 2014; 15 1 72 79
121. Smith K. R., Suppiah V., O'Connor K., et al. International Hepatitis C Genetics Consortium (IHCGC). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med: 2011; 3 8 57
122. Thomas E., Gonzalez V. D., Li Q., et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology: 2012; 142 4 978 988
123. Park H., Serti E., Eke O., et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology: 2012; 56 6 2060 2070
124. Sheahan T., Imanaka N., Marukian S., et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe: 2014; 15 2 190 202
125. Marcello T., Grakoui A., Barba-Spaeth G., et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology: 2006; 131 6 1887 1898
126. Bolen C. R., Ding S., Robek M. D., Kleinstein S. H. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology: 2014; 59 4 1262 1272
127. Jilg N., Lin W., Hong J., et al. Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology: 2014; 59 4 1250 1261
128. Giugliano S., Kriss M., Golden-Mason L., et al. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology: 2015; 148 2 392 402.e13
129. Winau F., Hegasy G., Weiskirchen R., et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity: 2007; 26 1 117 129
130. Wang Y., Li J., Wang X., Ye L., Zhou Y., Ho W. Induction of interferon-λ contributes to Toll-like receptor-3-activated hepatic stellate cell-mediated hepatitis C virus inhibition in hepatocytes. J Viral Hepat: 2013; 20 6 385 394
131. Griffiths S. J., Koegl M., Boutell C., et al. A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog: 2013; 9 8 e1003514
132. Akay E., Patel M., Conibear T., Chaggar T., Haque T. Interleukin 28B gene polymorphisms and Epstein-Barr virus-associated lymphoproliferative diseases. Intervirology: 2014; 57 2 112 115
133. Egli A., Levin A., Santer D. M., et al. Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus. J Infect Dis: 2014; 210 5 717 727
134. Bravo D., Solano C., Giménez E., et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol: 2014; 86 5 838 844
135. Bibert S., Wojtowicz A., Taffé P., et al. Swiss HIV Cohort Study. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS: 2014; 28 13 1885 1889
136. Manuel O., Wójtowicz A., Bibert S., et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis: 2015; 211 6 906 914
137. Treviño A., Lopez M., Vispo E., et al. HTLV Spanish Study Group. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis: 2012; 55 1 e1 e4
138. Sanabani S. S., Nukui Y., Pereira J., et al. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect Dis: 2012; 12 374
139. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog: 2008; 4 3 e1000017
140. Baldridge M. T., Nice T. J., McCune B. T., et al. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science: 2015; 347 6219 266 269
141. Nice T. J., Baldridge M. T., McCune B. T., et al. Interferon λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science: 2015; 347 6219 269 273
142. Pott J., Mahlakõiv T., Mordstein M., et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A: 2011; 108 19 7944 7949
143. Mordstein M., Kochs G., Dumoutier L., et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog: 2008; 4 9 e1000151
144. Mordstein M., Neugebauer E., Ditt V., et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol: 2010; 84 11 5670 5677
145. Contoli M., Message S. D., Laza-Stanca V., et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med: 2006; 12 9 1023 1026
146. Thomas D. L., Astemborski J., Rai R. M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA: 2000; 284 4 450 456
147. Grebely J., Raffa J. D., Lai C., Krajden M., Conway B., Tyndall M. W. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol: 2007; 21 7 447 451
148. Muir A. J., Bornstein J. D., Killenberg P. G.; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med: 2004; 350 22 2265 2271
149. Conjeevaram H. S., Fried M. W., Jeffers L. J., et al. Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology: 2006; 131 2 470 477
150. Key F. M., Peter B., Dennis M. Y., et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet: 2014; 10 10 e1004681
151. Suppiah V., Gaudieri S., Armstrong N. J., et al. International Hepatitis C Genetics Consortium (IHCGC). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study. PLoS Med: 2011; 8 9 e1001092
152. Raj T., Kuchroo M., Replogle J. M., Raychaudhuri S., Stranger B. E., De Jager P. L. Common risk alleles for inflammatory diseases are targets of recent positive selection. Am J Hum Genet: 2013; 92 4 517 529
153. Forni D., Cagliani R., Pozzoli U., et al. A 175 million year history of T cell regulatory molecules reveals widespread selection, with adaptive evolution of disease alleles. Immunity: 2013; 38 6 1129 1141
154. Casto A. M., Feldman M. W. Genome-wide association study SNPs in the human genome diversity project populations: does selection affect unlinked SNPs with shared trait associations? PLoS Genet: 2011; 7 1 e1001266
155. Barreiro L. B., Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet: 2010; 11 1 17 30
156. Single R. M., Martin M. P., Gao X., et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet: 2007; 39 9 1114 1119
157. Akuta N., Suzuki F., Kawamura Y., et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol: 2007; 46 3 403 410
158. Kobayashi M., Suzuki F., Akuta N., et al. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol: 2012; 47 5 596 605
159. Akuta N., Suzuki F., Seko Y., et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology: 2012; 56 6 2134 2141
160. Hayes C. N., Kobayashi M., Akuta N., et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut: 2011; 60 2 261 267
161. Lawitz E., Poordad F. F., Pang P. S., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet: 2014; 383 9916 515 523
162. Miura M., Maekawa S., Sato M., et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res: 2014; 44 14 E360 E367
163. Rose R., Markov P. V., Lam T. T., Pybus O. G. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. Infect Genet Evol: 2013; 20 418 421
164. Patin E., Kutalik Z., Guergnon J., et al. Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology: 2012; 143 5 1244 1252.e1, 12
165. Urabe Y., Ochi H., Kato N., et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol: 2013; 58 5 875 882
166. Calvaruso V., Bronte F., Grimaudo S., Di Cristina A., Di Marco V. Rs4374383 single nucleotide polymorphism of mertk gene influences the progression of liver fibrosis in thalassemia major patients with chronic hepatitis C virus infection. J Hepatol: 2013; 58 S182
167. Rüeger S., Bochud P. Y., Dufour J. F., et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut: 2015; 64 10 1605 1615
168. Rojas L., Ampuero J., Del Campo J. A., et al. Validation study of the impact of SNPs from GWAS associated with fibrosis progression in chronic hepatitis C (HCV). Hepatology: 2013; 58 4 01 327A
169. Tamaki N., Kurosaki M., Yasui Y., et al. Association of genetic polymorphisms with fibrosis progression in chronic hepatitis c after failure of interferon therapy. J Hepatol: 2014; 60 1 01 S315
170. Kumar V., Kato N., Urabe Y., et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet: 2011; 43 5 455 458
171. Miki D., Ochi H., Hayes C. N., et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet: 2011; 43 8 797 800
172. Harada Y., Kanehira M., Fujisawa Y., et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res: 2010; 70 14 5829 5839
173. Seng T. J., Ichimura K., Liu L., Tingby O., Pearson D. M., Collins V. P. Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 tile path array analysis. Genes Chromosomes Cancer: 2005; 43 2 181 193
174. Ishida S., Picard F., Rudolf G., et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet: 2013; 45 5 552 555
175. Ma N., Zhang X., Yu F., et al. Role of IFN-ks, IFN-ks related genes and the DEPDC5 gene in hepatitis B virus-related liver disease. J Viral Hepat: 2014; 21 7 e29 e38
176. Nagaoki Y., Aikata H., Kobayashi T., et al. Hepatocellular carcinoma development of hepatitis C virus patients with eradication to interferon therapy: a large scale, long-term study of 2266 patients. Hepatology: 2014; 60 01 1162A 1163A
177. Fellay J., Thompson A. J., Ge D., et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature: 2010; 464 7287 405 408
178. Tanaka Y., Kurosaki M., Nishida N., et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet: 2011; 20 17 3507 3516
179. Thompson A. J., Clark P. J., Singh A., et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol: 2012; 56 2 313 319
180. Zignego A. L., Wojcik G. L., Cacoub P., et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun: 2014; 15 7 500 505
181. McClellan J., King M. C. Genetic heterogeneity in human disease. Cell: 2010; 141 2 210 217
182. Manolio T. A., Collins F. S., Cox N. J., et al. Finding the missing heritability of complex diseases. Nature: 2009; 461 7265 747 753
183. Ward L. D., Kellis M. Interpreting noncoding genetic variation in complex traits and human disease. Nat Biotechnol: 2012; 30 11 1095 1106